TechNavio recognizes the following companies as the key players in the Global Personalized Medicine Diagnostics market: Abbott Laboratories, Agilent Technologies Inc., Becton Dickinson and Co., bioMerieux SA, Illumina Inc., and Roche Holding AG
Commenting on the report, an analyst from TechNavio’s team said: “One of the main trends witnessed in the Global Personalized Medicine Diagnostics market is the development of innovative tools and technologies. For instance, AssureRx Health Inc. launched GeneSightRx ADHD in May 2012, a personalized medicine test for the growing number of children and adults diagnosed with ADHD. Moreover, Bristol-Myers Squibb Co. collaborated with MMRF in December 2012 for advanced personalized medicine for multiple Myeloma. Further, Alacris Theranostics GmbH entered into an agreement with GlaxoSmithKline plc in November 2012 to use ModCell system for early stage cancer research. Furthermore, AltheaDx Inc. launched FLT3 Mutation Assay in October 2012. Agendia N.V. launched ColoPrint microarray-based 18-gene expression signature in June 2012 to predict the risk of distant recurrence for stage II colon cancer patients. The European Medicines Agency approved Zelboraf, manufactured by F. Hoffmann-La Roche Ltd., in December 2011.”
According to the report, one of the main factors driving the market is the increasing demand for personalized medicine diagnostics for treatment of cancer. Hyperthermia is one of the treatments of cancer where the use of personalized medicines and diagnostics is considered depending on a patient’s specific attributes. Methods of treatments such as hyperthermia and radiotherapy have already been proposed.
Further, the report states that one of the main challenges is low awareness about personalized medicine diagnostics in developing countries. Most of the patients in developing countries such as India and China are not fully aware of the recent developments in personalized medicine diagnostics. The high cost of personalized medicine diagnostics in certain treatments is another major challenge for the market in these countries.
The report also includes a discussion of the other vendors operating in this market. The other vendors in the market are 20/20 GeneSystems Inc., Accumetrics Inc., AdvanDx Inc., Affymetrix Inc., Agilent Technologies Inc., Almac Group Ltd., AltheaDx Inc., Ambry Genetics Corp., Amgen Inc., Arrayit Corp., AssureRx Health Inc., Autogenomics Inc., BG Medicine Inc., Biocare Medical LLC, Biocartis SA, Biocept Inc., BioCurex Inc., Biodesix Inc., Bio-Reference Laboratories Inc., bioMerieux SA, CombiMatrix Corp., Corgenix Medical Corp., DxTerity Diagnostics Inc., Enzo Biochem Inc., Epigenomics AG, Euroimmun AG, GE Healthcare, Genomic Health Inc., Illumina Inc., Interleukin Genetics Inc., Johnson & Johnson, Knome Inc., Lab21 Ltd., Life Technologies Corp., MDxHealth SA, Myriad Genetics Inc., Nanosphere Inc., Pathway Genomics Corp., Power3 Medical Products Inc., Quest Diagnostics Inc., Response Genetics Inc., Rosetta Genomics Ltd., Sequenom Inc., Trovagene Inc., Vermillion Inc., Viracor-IBT Laboratories Inc.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors. For further information on this report, please visit https://www.technavio.com/report/global-personalized-medicine-diagnostics…
TechNavio, the market research platform of Infiniti Research Ltd., publishes periodic market research reports on niche and emerging technologies. For more information on our market research, please visit https://www.technavio.com/healthcare-chemicals-food-retail
Follow us on Twitter @ Technavio
TechNavio Announces the Publication of its Research Report – Global Personalized Medicine Diagnostics Market 2012-2016
